MONEYVIEW vs SYMBIOTEC: Stock Comparison
Head-to-head financial and trading comparison between Moneyview Limited (MONEYVIEW) and Symbiotec Pharmalab Limited (SYMBIOTEC) in the Cross-Sector Peers sector.
MONEYVIEW
NSE: MONEYVIEWSYMBIOTEC
NSE: SYMBIOTECKey Metrics Comparison Table
| Metric | MONEYVIEW | SYMBIOTEC | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹53.88 | ₹1,198.00 | — |
| 1-Year Price Return | 0.0% | +9.14% | SYMBIOTEC (9.14% higher) |
| 52-Week High | ₹53.88 | ₹1,198.00 | — |
| 52-Week Low | ₹53.88 | ₹1,003.35 | — |
| 30-Day Annualized Volatility | 15.0% | 56.38% | MONEYVIEW (Steadier) |
| 30-Day Average Daily Volume | 655,464,953 | 3,302,737 | MONEYVIEW (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between MONEYVIEW and SYMBIOTEC, which stock gave better returns over the last year?
SYMBIOTEC has outperformed MONEYVIEW over the past 12 months with a gain of 9.14% compared to 0.0%.
Which stock is less volatile: MONEYVIEW or SYMBIOTEC?
MONEYVIEW demonstrated lower price volatility (15.0% annualized) compared to SYMBIOTEC (56.38%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of MONEYVIEW vs SYMBIOTEC?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are MONEYVIEW and SYMBIOTEC direct sector competitors?
Yes, both companies operate within the Cross-Sector Peers sector in India and are actively tracked as sector peers by institutional and retail market participants.